10/22/21 7:30 AMNasdaq : NTRB, NTRBWofferingNutriband Inc. Receives Additional $2,062,500 from Exercise of Warrants, Increasing Total Capital from Public Offering and Nasdaq Listing to Approx. $8.7MNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, is pleased to announce the receipt of $2,062,500 inRHEA-AIneutral
10/12/21 7:30 AMNasdaq : NTRB, NTRBWcovid-19Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator PatchNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products, today announced that it has signed an exclusiveRHEA-AIvery positive
10/05/21 3:35 PMNasdaq : NTRB, NTRBWofferingWestPark Capital Announces Completion of a $6.6 Million Public Offering for Nutriband Inc. (NASDAQ: NTRB) and Up-listing to the NASDAQ Capital MarketNutriband Inc., a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that its common stock and warrants began trading on the Nasdaq Capital Market effective October 1, 2021. Nutriband also announced the...RHEA-AIneutral
10/04/21 7:30 AMNasdaq : NTRB, NTRBWNutriband Inc.'s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO)Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, today announced thatRHEA-AIvery negative
10/01/21 12:00 PMNasdaq, OTC : NTRB, NTRBWofferingNutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital MarketNutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal products focused on preventing opioid abuse, announced that itsRHEA-AIneutral
10/01/21 9:45 AMOTC, Nasdaq : NTRB, NTRBWofferingNutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital MarketNutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermalRHEA-AIneutral
